CUMULATIVE INDEX Volume 18, Numbers 1-12, Pages 1-96 January 1999 — December 1999
CUMULATIVE INDEX Volume 18, Numbers 1-12, Pages 1-96 January 1999—December 1999
A
abciximab, 9:67
ablation, catheter, 4:31
ACE inhibitors, 8:62
acute MI, 2:12, 9:65, 12:93
adenosine, 4:28
alcohol consumption, 10:79
American College of Cardiology, 5:33, 6:41
American Heart Association, 12:89
amiodarone, 2:9, 11:83
angina, 1:1, 1:3
angiogenesis, 2:10
angiographic predictors, 6:46
angioplasty, 9:65
primary, 9:67
antiarrhythmics, 5:37
anticoagulants, 6:47
aortic debris, 6:47
arrhythmias
atrial, 9:68
ventricular, 2:12
ASD, 2:14
aspirin, 8:62
atherectomy
rotational, 3:17
atrial arrhythmias, 9:68
atrial fibrillation, 2:9, 7:55, 8:59, 12:92
nonvalvular, 6:44
AVID, 12:95
B
BEST, 12:90
beta blockers, 1:3, 3:18
bundle branch block, 1:4
C
CABG Patch, 5:38
calcium blockers, 12:94
cardiac arrest, 10:76, 11:83
cardiac death, 10:79
cardiac surgery, 10:78
cardiomyopathy
dilated, 7:53
cardioversion, 8:59, 10:77
catheter ablation, 4:31
CHF, 7:53
cholesterol, 3:20
LDL, 8:63
CLASICS, 5:37
coenzyme Q, 7:53
constrictive pericarditis, 2:15
coronary
disease, 6:45, 8:63
stenting, 7:49
syndromes, 4:30
CPR
ACD, 10:76
standard, 10:76
C-reactive protein, 10:75
D
defibrillators
implantable, 5:37
defibrillator shocks
implantable, 8:60
digoxin, 9:72
diltiazem, 1:3
dofetilide, 11:86
DSE, 9:71
E
ELITE II, 12:91
endocardial mapping, 1:7
EPS, 7:55
estrogen, 10:75
echocardiography
dobutamine stress, 4:27
exercise, 7:50
transesophageal, 2:11, 7:51
F
Framingham Heart Study, 3:22
FRISC II, 5:35
H
heart failure, 2:9, 3:18
congestive, 11:86
hirudin, 4:30
HOPE study, 12:89
I
ibutilide, 8:59, 9:68
ICDs, 7:53, 9:70
immune system activation, 1:1
implantable
defibrillators, 5:37
defibrillator shocks, 8:60
L
LDL cholesterol, 8:63
left ventricle, 1:7
LV dilation, 2:13
M
Merit-Heart Failure, 6:41
MI, 6:46, 9:72
acute, 2:12, 9:65, 12:93
MR, 3:21, 4:29
MUSTT, 6:42
MVP, 8:57
myopathy, 12:94
N
nonvalvular atrial fibrillation, 6:44
O
obesity, 11:87
open artery hypothesis, 1:6
OPUS, 5:36
P
pericarditis
constrictive, 2:15
PET, 9:71
polyunsaturated fatty acids
marine, 10:73
protein
C-reactive, 10:75
PTCA, 12:93
pulmonary venous flow reversal, 4:29
Q
QT, 10:77
R
recurrent syncope, 12:91
renin-angiotensin access, 11:84
reperfusion, 9:65
restenosis, in-stent, 3:17, 3:19
S
SHOCK, 5:33
sotalol, 7:55, 8:60
stenting, coronary, 7:49
stroke, 3:20, 10:78
stroke prevention, 12:92
superior vena cava Doppler, 2:15
surveillance systems, 9:70
SVT, 4:28
syncope, 3:23, 7:53
recurrent, 12:91
T
tachycardia, ventricular, 1:4, 6:43
thrombocytopenia
heparin-induced, 10:75
thrombolysis, 9:67
thrombolytic therapy, 12:93
tilt table training, 12:91
TMLR, 4:25
TMR, 11:81
transcatheter closure, 2:14
trials
American College of Cardiology, 5:33, 6:41
American Heart Association, 12:89
AVID, 12:95
BEST, 12:90
CABG Patch, 5:38
CLASICS, 5:37
ELITE II, 12:91
FRISC II, 5:35
Merit-Heart Failure, 6:41
MUSTT, 6:42
OPUS, 5:36
SHOCK, 5:33
U
ultrasound predictors
angiographic, 3:19
intravascular, 3:19
V
ventricle
left, 1:7
ventricular arrhythmias, 2:12
vitamin E, 10:73
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.